worth of notice:
quote:
"THE GOAL OF REPLACEMENT gene therapy is to replace faulty genes with normal ones, in the hope of producing significant benefits or even cures. The process involves packaging healthy genes into neutered viruses, usually relatively harmless adeno-associated viruses, which then act as vectors delivered in a single dose either into the bloodstream or the area where the disease is manifest. The neutered viruses are designed to attach to targeted cells and deliver the new genes into the nucleus of the cells, along with so-called promoters that help prompt the new genes to direct cells to make critical proteins that are otherwise lacking or ineffective. ...
...A big issue for the industry and investors will be gene therapy pricing. At a time when treatments for rare diseases that need to be dosed indefinitely can cost $400,000 annually or more, how should a potential one-time cure be priced? Gene therapy companies haven’t said yet how they plan to price treatments, and Wall Street analysts and investors have said price tags of anywhere from $1 million to $4 million per patient for serious diseases could be justified when there are no alternatives—or when less effective alternative treatments cost more over time....
The current treatment for spinal muscular atrophy, Biogen’s (BIIB) Spinraza, was approved by the FDA last year. It costs $750,000 for the first year’s treatment and $375,000 a year thereafter..... A pay-for-performance model might develop, with annual payments based on continued success, but that raises issues of portability....
...Replacement gene therapy reduces the chances of a potentially harmful off-target genetic insertion that could lead to cancer. But there are risks, including a possible immune-system response to the vectors. One of the most serious incidents occurred in 1999, when an 18-year-old patient receiving experimental replacement gene therapy died from a severe immune response....
...If these treatments ultimately stop working, it might be difficult to re-treat patients with the same therapy because their bodies probably will have developed immunity to the viral vectors that initially delivered new genes. That means the viruses probably would be attacked by the patient’s immune system. Some companies are working on ways to address this issue, such as using different viral vectors...."
https://goo.gl/sP8B8v
critical process died 在 請教如何解決critical process died - Mobile01 的八卦
請教如何解決critical process died - 如標題要如何解決critical process died每次開機之後用不到一分鐘就當掉了根本用不了電腦請各位麻煩一下 ... ... <看更多>